[Drug prevention and therapy of ventricular tachycardia].
Antiarrhythmic drugs of type I to IV (Vaughan Williams) are generally used for the treatment of ventricular tachycardia, especially in patients with symptomatic and hemodynamically not tolerated arrhythmias; however, randomized controlled studies revealed a beneficial effect on sudden cardiac death only for type-II (beta-blocking agents) and type-III (Amiodarone) antiarrhythmic drugs. These drugs are, therefore, the antiarrhythmic agents of first choice; but, in addition, underlying heart disease, triggering factors and heart-rate dependency should be considered.
Burckhardt
D
D
Abteilung Kardiologie, Universitätsspital Basel.
Hoffmann
A
A
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology; D003645:Death, Sudden / Q000209:etiology; D004562:Electrocardiography / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents
Medikamentöse Prophylaxe und Therapie der Kammertachykardie.